MaxCyte has developed a novel and proprietary platform for next-generation chimeric antigen receptor (CAR)-engineered cell therapies. Our CARMA™ platform employs human mRNA with no viral component and provides several unique attributes over existing autologous CAR products and platforms.
This platform offers the potential to deliver therapy to the patient in in a fraction of the time with less complexity of other autologous CAR-T products. This is due to a more streamlined manufacturing process without the complexity of virus-based products.
Equally as important, MaxCyte’s CAR cell therapies use human mRNA to engineer immune cells, specifically PBMCs (peripheral blood mononuclear cells) that provide a transient and controlled persistence via multi-doses. This has been shown in non-clinical studies to reduce tumor burden and extend survival.
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter